Increased PRIM2 expression associated with poor-prognosis in patients with pancreatic ductal adenocarcinoma.

IF 1.7 4区医学 Q3 GASTROENTEROLOGY & HEPATOLOGY

Pancreas Pub Date : 2024-09-12 DOI:10.1097/mpa.0000000000002387

Jingyang Yin,Shixiang Guo,Jiali Yang,Renpei Xia,Huaizhi Wang

{"title":"Increased PRIM2 expression associated with poor-prognosis in patients with pancreatic ductal adenocarcinoma.","authors":"Jingyang Yin,Shixiang Guo,Jiali Yang,Renpei Xia,Huaizhi Wang","doi":"10.1097/mpa.0000000000002387","DOIUrl":null,"url":null,"abstract":"OBJECTIVES\r\nTo explore the association between PRIM2 expression and prognosis of patients with pancreatic ductal adenocarcinoma (PDAC) from multi clinic centers.\r\n\r\nMETHODS\r\nSamples from PDAC patients were collected and processed to tissue microarray (TMA). PRIM2 expression was detected by immunohistochemistry (IHC) of in 127 enrolled PDAC patients, which underwent surgical resection from January 2012 to December 2018, with complete follow-up, were enrolled and grouped by PRIM2 stain level into two groups. The expression differences, the association to clinicopathologic features and the survival were evaluated by the groups. Data of RNA/protein expression and clinical features from public databases were used for validation.\r\n\r\nRESULTS\r\nPRIM2 was highly expressed in PDAC patients and associated with poor-prognosis in patients with PDAC. Association was found between increased PRIM2 levels and pathology grade (p = 0.050). Moreover, in multivariate analysis of survival, the highly expression of PRIM2 was identified as an independent risk factor for poor survival (HR1.78, p = 0.031). Analysis on public databases validated above results.\r\n\r\nCONCLUSIONS\r\nHigh expression of PRIM2 associated with poor prognosis in PDAC patients, PRIM2 could be used as an independent risk indicator.","PeriodicalId":19733,"journal":{"name":"Pancreas","volume":"10 1","pages":""},"PeriodicalIF":1.7000,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pancreas","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/mpa.0000000000002387","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

OBJECTIVES To explore the association between PRIM2 expression and prognosis of patients with pancreatic ductal adenocarcinoma (PDAC) from multi clinic centers. METHODS Samples from PDAC patients were collected and processed to tissue microarray (TMA). PRIM2 expression was detected by immunohistochemistry (IHC) of in 127 enrolled PDAC patients, which underwent surgical resection from January 2012 to December 2018, with complete follow-up, were enrolled and grouped by PRIM2 stain level into two groups. The expression differences, the association to clinicopathologic features and the survival were evaluated by the groups. Data of RNA/protein expression and clinical features from public databases were used for validation. RESULTS PRIM2 was highly expressed in PDAC patients and associated with poor-prognosis in patients with PDAC. Association was found between increased PRIM2 levels and pathology grade (p = 0.050). Moreover, in multivariate analysis of survival, the highly expression of PRIM2 was identified as an independent risk factor for poor survival (HR1.78, p = 0.031). Analysis on public databases validated above results. CONCLUSIONS High expression of PRIM2 associated with poor prognosis in PDAC patients, PRIM2 could be used as an independent risk indicator.

查看原文本刊更多论文

胰腺导管腺癌患者的 PRIM2 表达增加与预后不良有关。

目的探讨来自多个临床中心的胰腺导管腺癌（PDAC）患者的PRIM2表达与预后之间的关联。方法收集PDAC患者的样本并处理成组织芯片（TMA）。通过免疫组化（IHC）检测2012年1月至2018年12月期间接受手术切除、随访完整的127例PDAC患者的PRIM2表达，并按PRIM2染色水平分为两组。各组患者的表达差异、与临床病理特征的关联以及生存率均接受了评估。结果PRIM2在PDAC患者中高表达，与PDAC患者的不良预后相关。PRIM2水平升高与病理分级之间存在关联（p = 0.050）。此外，在生存率的多变量分析中，PRIM2 的高表达被确定为生存率低的独立风险因素（HR1.78，p = 0.031）。结论PRIM2的高表达与PDAC患者的不良预后有关，PRIM2可作为一个独立的风险指标。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pancreas 医学-胃肠肝病学

CiteScore

4.70

自引率

3.40%

发文量

289

审稿时长

1 months

期刊介绍： Pancreas provides a central forum for communication of original works involving both basic and clinical research on the exocrine and endocrine pancreas and their interrelationships and consequences in disease states. This multidisciplinary, international journal covers the whole spectrum of basic sciences, etiology, prevention, pathophysiology, diagnosis, and surgical and medical management of pancreatic diseases, including cancer.